Alkeran

This page contains recent news articles, when available, and an overview of Alkeran but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

Overview:

Alkeran (when available)

Pharmacology and use:
Melphalan is an antineoplastic in the class of alkylating agents and is used to treat various forms of cancer. Alkylating agents are so named because of their ability to add alkyl groups to many electronegative groups under conditions present in cells. They stop tumor growth by cross-linking guanine bases in DNA double-helix strands - directly attacking DNA. This makes the strands unable to uncoil and separate. As this is necessary in DNA replication, the cells can no longer divide. In addition, these drugs add methyl or other alkyl groups onto molecules where they do not belong which in turn inhibits their correct utilization by base pairing and causes a miscoding of DNA. Alkylating agents are cell cycle-nonspecific. Alkylating agents work by three different mechanisms all of which achieve the same end result - disruption of DNA function and cell death. Used to treat cancer of the ovaries and a certain type of cancer in the bone marrow

Mechanism Of Action:
Alkylating agents work by three different mechanisms: 1) attachment of alkyl groups to DNA bases, resulting in the DNA being fragmented by repair enzymes in their attempts to replace the alkylated bases, preventing DNA synthesis and RNA transcription from the affected DNA, 2) DNA damage via the formation of cross-links (bonds between atoms in the DNA) which prevents DNA from being separated for synthesis or transcription, and 3) the induction of mispairing of the nucleotides leading to mutations.

News Articles on Melphalan

Celgene Corp. Reports Operating Results (10-Q)  -  ‎Oct 30, 2009‎
...due to the inclusion of residual payments earned by us based upon GSK's ALKERAN® revenues subsequent to the conclusion of the ALKERAN® license with GSK. ... GuruFocus.com

Multiple Myeloma Study Finds “Complete Response�? Is Generally Correlated With ...  -  ‎Oct 20, 2009‎
In newly diagnosed patients, the authors noted that a combination of melphalan (Alkeran), prednisone, and thalidomide yielded higher response rates and ... The Myeloma Beacon

Treatment Trends For Multiple Myeloma – Part 1: Autologous Stem Cell Transplants  -  ‎Nov 3, 2009‎
A group of researchers in France found that Velcade and high-dose melphalan (Alkeran) make for a “safe and highly effective�? preparatory treatment in a ... The Myeloma Beacon

Afternoon Report - CELG - Celgene asks for Revlimid approval  -  ‎Jul 8, 2009‎
The company also sells ALKERAN for the palliative treatment of multiple myeloma and of carcinoma of the ovary; VIDAZA, which is used for the treatment of TransWorldNews (press release)

New Report Just Published: World Multiple Myeloma Therapeutics ...  -  ‎Jul 7, 2009‎
Arsenal Against Multiple Myeloma II-5 Velcade(R) (Bortezomib) II-5 Thalomid(R) (Thalidomide) II-5 Revlimid(R) (Lenalidomide) II-6 Alkeran (Melphalan) PR Newswire (press release)

Autologous Stem Cell Transplantation Effective for High-risk ...  -  ‎Mar 4, 2009‎
...[3] In another study, researchers in England performed a randomized trial evaluating high-dose Alkeran® (melphalan) in children with advanced neuroblastoma Cancer Consultants

Celgene Posts Q4 Loss, Non GAAP EPS Doubles; Sees FY'09 EPS Growth ...  -  Jan 29, 2009
The company's marketed drugs include Thalomid/Thalidomide, Revlimid, Vidaza, Alkeran and Focalin. Focalin, a drug to treat Attention Deficit Hyperactivity RTT News,

Market Report -- In Play (CELG)  -  Jan 29, 2009
...$70.6 mln First Call Consensus; Alkeran $24.4 mln vs. $19.8 mln First Call Consensus. Briefing.com is the leading Internet provider of live market analysis MSN Money

Celgene Corp. - Relatively Benign  -  Jan 12, 2009
The company's marketed drugs include Thalomid/Thalidomide, Revlimid, Vidaza, Alkeran and Focalin. Focalin, a drug to treat Attention Deficit Hyperactivity RTT News,

Celgene Corp. Q4 2008 Earnings Call Transcript  -  Jan 29, 2009
In addition, as of March 31, we will no longer commercialize Alkeran, due to the conclusion of our agreement with GlaxoSmithKline. Revenues for Alkeran were Seeking Alpha,

Pharma Earnings In Q4 - Healthy Or Ailing?  -  Jan 25, 2009
The company's marketed drugs include Thalomid/Thalidomide, Revlimid, Vidaza, Alkeran and Focalin. Revlimid, a drug approved for the treatment of Trading Markets (press release),

CyDex Pharmaceuticals Receives Orphan-Drug Designation for Melphalan  -  Dec 8, 2008
Melphalan is an FDA-approved chemotherapy for multiple myeloma marketed under the brand name Alkeran ® by GlaxoSmithKline. Alkeran is packaged as two Business Wire (press release),

美 2개 암 치료제 �?�귀약 지정  -  Dec 9, 2008
...사�?��?�스�?� 멜파란�?� '캡티솔'(CAPTISOL) 약물전달 기술�?� 통해 기존�?� 화학요법제�?� ‘알케란’(Alkeran)�?� 개선시킨 제제로, 알케란�?� 사용�?전 �? 개�?� 분리�?� 바�?�알 디지틀보사,

Addition of thalidomide to melphalan and prednisolone improved PFS ...  -  Oct 29, 2008
The median PFS was 21.8 months for the melphalan (Alkeran, GlaxoSmithKline), prednisone and thalidomide (MPT) group and 14.5 months for the melphalan and HemOncToday,

Velcade Combination Treatment Outperforms Standard  Sep 2, 2008
Takeda Pharmaceutical’s Velcade, combined with GlaxoSmithKline’s Alkeran and prednisone, proved superior to the latter two drugs alone in patients withFDA news (subscription),

Addition of Velcade® to Standard Therapy Improves Survival in ...  Aug 29, 2008
Standard initial therapy for patients with multiple myeloma who are not eligible for a stem cell transplant is the chemotherapy agent Alkeran plus theCancer Consultants,

Using Velcade as part of initial treatment for myeloma improves ...  Sep 3, 2008
The standard treatment for multiple myeloma, a blood cell cancer, is taking the drugs Alkeran (melphalan) and prednisone. Velcade (bortezomib) has also beenAbout - News & Issues,

Bortezomib plus melphalan-prednisone improved response rate in ...  Sep 5, 2008
Millennium Pharmaceuticals Inc.) to combination melphalan (Alkeran, GlaxoSmithKline) and prednisone is superior to melphalan plus prednisone alone inHemOncToday,

Bortezomib (Velcade) in Combo Scores For Initial Myeloma Treatment  Aug 27, 2008
...bortezomib (Velcade) appears effective as a first-line therapy when added to standard melphalan (Alkeran) and prednisone, found a phase III trial.MedPage Today,

Combination Therapy Helps to Combat Myeloma  Aug 27, 2008
And complete responses to treatment were seen among 30 percent of those receiving Velcade, compared to 4 percent for those given Alkeran and prednisoneWashington Post,

Biogen Idec and Elan Corp Announce Start of Trials with Tysabri as ...  Sep 5, 2008
...with sales for $ 613 million dollars in the first 6 months of the year; Thalomid, sales for $ 245 million dollars in the same period; and Alkeran.Network Médica,

183ème édition des LIDD : Liens Idiots Du Dimanche  Aug 16, 2008
...(Merci Alkeran) - Beatbox : un beatboxeur français de grand talent fait une desmontration fantastique ! Si le début est « tranquille », au bout d'un certainPC Inpact,

Celgene Corp. Q2 2008 Earnings Call Transcript  -  Jul 24, 2008
ALKERAN, net product sales generated $20 million versus $19 million in 2007. Excluded from non-GAAP revenues for the second quarter our product sales of Seeking Alpha,

Celgene Reports Record Second Quarter 2008 Product Sales and ...  -  Jul 24, 2008
ALKERAN ® net sales for the second quarter of 2008 were $20.4 million compared to $18.7 million in the second quarter of 2007. Revenue from Focalin™ and the Business Wire (press release),

Velcade® Approved for Initial Therapy of Multiple Myeloma  -  Jun 23, 2008
The VISTA trial compared Velcade/Alkeran/prednisone to Alkeran/prednisone only as initial treatment among patients with multiple myeloma. Cancer Consultants,

Celgene Corp. Q1 2008 Earnings Call Transcript  -  May 8, 2008
ALKERAN net product sales generated $15.1 million. Not included in our non-GAAP revenue for the quarter are product sales of Innohep and Refludan whose Seeking Alpha,

Celgene Reports Record First Quarter 2008 Product Sales and ...  -  May 8, 2008
ALKERAN(R) net sales for the first quarter of 2008 were $15.1 million compared to $16.0 million in the first quarter of 2007. Revenue from Focalin(TM) and PharmaLive.com (press release),

Brand Names/Synonyms:
Alkeran is also known by the following brand names and/or synonyms:
3025 C. B.; ALKERAN; AT-290; Alkeran; CB 3025; L-PAM; L-Phenylalanine Mustard; L-Sarcolysin; L-Sarcolysine; L-Sarkolysin; Levofalan; Melfalan; Melphalan; Mephalan; NSC 8806; NSC-8806; Phenylalanine Mustard; Phenylalanine Nitrogen Mustard; Sarcolysine; Sarkolysin

Drug Category:
Alkeran is categorized under the following by the FDA: Antineoplastic Agents; ATC:L01AA03

Dosage Forms:
tablets, injection

Absorption:
incomplete, variable, 25-89% post oral dose

Interactions:
[an error occurred while processing this directive]

Chemical IUPAC Name:
2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]-propanoicacid

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on cancernewsnetwork.org lead to other sites. cancernewsnetwork.org does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is CancerNewsNetwork.org responsible for dead or misdirected links.

IF YOU NEED A LINK OR TEXT REMOVED FROM THIS PAGE PLEASE CONTACT cancernewsnetwork (at) live.com.
We will do our best to accommodate your request.